P-021 Durable response to CAR T cell treatment is associated with the downstream triggering of native T cell immunity: a lesson learned from B cell lymphoma patients
Dimitra Karagkouni(University of Thessaly), Ioannis S. Vlachos(Broad Institute), Eleni Kanata(Broad Institute), Gayatri Tiwari, David Avigan(Beth Israel Deaconess Medical Center), Jacalyn Rosenblatt(Beth Israel Deaconess Medical Center), Jenny Kim, Yered Pita-Juárez(Broad Institute), Giulia Cheloni(Tumour Institute of Tuscany), Zachary M. Avigan(Icahn School of Medicine at Mount Sinai), Dina Stroopinsky(Beth Israel Deaconess Medical Center), Daniela Torres(Beth Israel Deaconess Medical Center), Brodie Miles(Children's Cancer Therapy Development Institute), Jessica Liegel(Beth Israel Deaconess Medical Center), Mike Mattie
Cited by 0
Related Papers
DIANA-miRPath v3.0: deciphering microRNA function with experimental support
|Nucleic Acids Research|2015|1.8k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility
|Science|2019|1.4k
DIANA-TarBase v8: a decade-long collection of experimentally supported miRNA–gene interactions
|Nucleic Acids Research|2017|1.2k
DIANA-microT web server v5.0: service integration into miRNA functional analysis workflows
|Nucleic Acids Research|2013|1.2k